Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
08:00am, Monday, 12'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of Stock
05:24am, Tuesday, 06'th Jan 2026
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.93,
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 05'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of “Moderate Buy” by Brokerages
05:45am, Monday, 29'th Dec 2025
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat Ratings reports. One r
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
02:00am, Saturday, 27'th Dec 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two c
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty phar
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.30 Consensus Price Target from Brokerages
02:14am, Sunday, 07'th Dec 2025
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports.
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
04:05pm, Wednesday, 19'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonst
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
09:00am, Friday, 07'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Hea
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
09:41pm, Wednesday, 05'th Nov 2025
Vir Biotechnology, Inc. ( VIR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark Eisner - Executive V
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
06:46pm, Wednesday, 05'th Nov 2025
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quart
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
08:00am, Monday, 03'rd Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 22'nd Oct 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended Septemb
